The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Complications of hyperglycemia in phase 1 trials targeting the PI3K-akt-mTOR (PAM) pathway.
Elena Geuna
No relevant relationships to disclose
Desamparados Roda
No relevant relationships to disclose
Saeed Rafii
No relevant relationships to disclose
Begona Jimenez
No relevant relationships to disclose
Marta Capelan
No relevant relationships to disclose
Karim Rihawi
No relevant relationships to disclose
Timothy Anthony Yap
No relevant relationships to disclose
Stanley B. Kaye
No relevant relationships to disclose
Johann Sebastian De Bono
No relevant relationships to disclose
L Rhoda Molife
No relevant relationships to disclose
Udai Banerji
No relevant relationships to disclose